Amino-caprolactam derivatives as γ-secretase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 21, 2007, Pages 5790-5795

  Parker, Michael F ^a   Bronson, Joanne J ^a   Barten, Donna M ^a   Corsa, Jason A ^a   Du, Wengsheng ^a   Felsenstein, Kevin M ^a   Guss, Valerie L ^a   Izzarelli, Darcy ^a   Loo, Alice ^a   McElhone, Kate E ^a   Marcin, Larry R ^a   Padmanabha, Ramesh ^a   Pak, Roger ^a   Polson, Craig T ^a   Toyn, Jeremy H ^a   Varma, Sam ^a   Wang, Jian ^a   Wong, Victoria ^a   Zheng, Ming ^a   Roberts, Susan B ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Secretase inhibitors; Alzheimer's disease; N Benzyl amino caprolactams

Indexed keywords

AMINOCAPROLACTAM DERIVATIVE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; GAMMA SECRETASE INHIBITOR; SULFONAMIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; BRAIN LEVEL; DEGENERATIVE DISEASE; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TRANSGENIC MOUSE;

AMYLOID PRECURSOR PROTEIN SECRETASES; CAPROLACTAM; ENZYME INHIBITORS;

EID: 34548858715     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.08.047     Document Type: Article

References (15)

1. Scheff S.W., Price D.A., Schmitt F.A., and Mufson E.J. Neurobiol. Aging 27 (2006) 1372
2. Clark C.M., and Karlawish J.H. Ann. Intern. Med. 138 (2003) 400
3. Hardy J., and Higgins G.A. Science 256 (1992) 184
4. Nguyen J., Yamani A., and Kiso Y. Curr. Pharm. Des. 12 (2006) 4295
5. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe S., Rowan M.J., and Delkow D.J. Nature 416 (2002) 535
6. Selkow D.J., Podlisny M.B., Joachim C.l., Vickers E.A., Lee G., Fritz L.C., and ltersdorf T. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 7341
7. 50 values determined using curve fitting in CurveMaster (Excel-Fit based data analysis package). Also, see Smith, D. W.; Munoz, B.; Srinirvasan, K.; Bergstrom, C. P.; Chaturvedula, P. V.; Deshpande, M. S.; Keavy, D. J.; Lau, W. Y.; Parker, M. F.; Sloan, C. P.; Wallace, O. B.; Wang, H. H. WO 0050391.
8. Roberts, S. B.; Hendrick, J. P.; Vinitsky, A.; Lewis, M.; Smith, D. W.; Pak, R. Isolation of functionally active γ-secretase presenilin 1 complex and fluorescence assay for γ-secretase activity and inhibitors. US 2004, 0121411 A1.
9. Purchased from ComGenex Corporation as part of a collection of sulfonamides.
10. Recently disclosed in a patent, Martin, N.; preparation of N-substituted heterocyclic sulfonamides for treating cognitive disorders. US 2006/0270657A1.
11. Pellegata R., Pinza G., and Pifferi G. Synthesis (1978) 614
12. The 3 amino-2-piperidone was synthesized from d-ornithine following the method of Pellegata (9). The 3-amino-2-pyrrolidinone was purchased from Ramidus AB.
13. Possible clarifications for the 10-fold increase in activity include but are not limited to: antagonism or partial agonist activity by the inactive enantiomer, chiral ligand regulated enzyme activity, allosteric binding by one of the enantiomers or even relative error in the binding assay. These hypothetical explanations are being explored further.
14. Determination of Aβ, full length APP, and APP carboxy-terminal fragments, brain tissues was performed following the procedure as described previously. Barten D.M., Guss V.L., Corsa J.A., Loo A., Hansel S.B., Zheng B., Munoz K., Srinivasan K., Wang B., Roberson B.J., Polson C.T., Wang J., Roberts S.B., Hendrick J.P., Anderson J.J., Loy J.K., Denton R., Verdoorn T.A., Smith D.W., and Felsenstein K.M. J. Pharmacol. Exp. Ther. 312 (2005) 635
15. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Science 274 (1996) 99